# OnCo record follicular-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/follicular-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "follicular-lymphoma" ;
  schema:name "Follicular lymphoma"@en ;
  schema:description "Follicular lymphoma is the most common slow-growing lymphoma, defined in about 85% of cases by a BCL2 translocation. Most people live with it for decades, treated only when it causes problems; it can be controlled repeatedly with anti-CD20 antibodies, chemotherapy, bispecifics or CAR-T but rarely cured, and a small share transform into an aggressive lymphoma each year."@en ;
  schema:url <https://onco.cc/cancers/follicular-lymphoma/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Follicular_lymphoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q123251> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480>, <https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq>, <https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/fl/> ;
  onco:tag "gap-fill", "haematologic" ;
  onco:related <https://onco.cc/collections/lymphoma-research-foundation/>, <https://onco.cc/cancers/marginal-zone-lymphoma/>, <https://onco.cc/cancers/waldenstrom/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/technologies/radioimmunotherapy/> ;
  onco:targets <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/cd3/>, <https://onco.cc/targets/bcl2/>, <https://onco.cc/targets/ezh2/>, <https://onco.cc/targets/btk/> ;
  onco:drugs <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/obinutuzumab/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/mosunetuzumab/>, <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/odronextamab/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/tisagenlecleucel/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/tazemetostat/>, <https://onco.cc/drugs/chlorambucil/>, <https://onco.cc/drugs/ibritumomab-tiuxetan/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/genmab/>, <https://onco.cc/companies/abbvie/>, <https://onco.cc/companies/gilead/>, <https://onco.cc/companies/beone/>, <https://onco.cc/companies/regeneron/>, <https://onco.cc/companies/haihe-biopharma/> ;
  onco:pathways <https://onco.cc/pathways/apoptosis-bcl2/> ;
  onco:terms <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/terms/histologic-transformation/>, <https://onco.cc/terms/deauville-score/>, <https://onco.cc/terms/flipi/> ;
  onco:trials <https://onco.cc/trials/nct07634471/>, <https://onco.cc/trials/nct07562022/>, <https://onco.cc/trials/nct06097364/>, <https://onco.cc/trials/nct04712097/>, <https://onco.cc/trials/nct06549595/>, <https://onco.cc/trials/nct06149286/>, <https://onco.cc/trials/nct06191744/>, <https://onco.cc/trials/nct06911502/>, <https://onco.cc/trials/nct04224493/>, <https://onco.cc/trials/nct01804686/>, <https://onco.cc/trials/nct04680052/>, <https://onco.cc/trials/nct06091254/>, <https://onco.cc/trials/nct05100862/>, <https://onco.cc/trials/nct05888493/>, <https://onco.cc/trials/nct05409066/>, <https://onco.cc/trials/nct05371093/>, <https://onco.cc/trials/augment/>, <https://onco.cc/trials/zuma-5/> ;
  onco:journals <https://onco.cc/journals/hematological-oncology/> ;
  onco:pipeline <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/mosunetuzumab/>, <https://onco.cc/drugs/odronextamab/>, <https://onco.cc/drugs/golcadomide/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/>, <https://onco.cc/drugs/abexinostat/>, <https://onco.cc/drugs/mk-1045/>, <https://onco.cc/drugs/sctb35/>, <https://onco.cc/drugs/xnw5004/>, <https://onco.cc/drugs/tc011/>, <https://onco.cc/drugs/crc01/>, <https://onco.cc/drugs/ctx112/> ;
  onco:standardOfCare <https://onco.cc/drugs/rituximab/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/trials/fort/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/obinutuzumab/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/trials/gallium/>, <https://onco.cc/trials/relevance/>, <https://onco.cc/drugs/mosunetuzumab/>, <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/tisagenlecleucel/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/odronextamab/> .